Pacific Diabetes Technologies, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-10-20.
Pacific Diabetes Technologies, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 20, 2025. The filing reports $3.38M sold. Its industry group is Biotechnology. It names Thomas Seidl (Executive Officer, Director, Promoter), Hank Wuh (Director), Christopher Marsh (Director) (SEC Form D/A, October 20, 2025).
Is this your company?
Sell to companies like Pacific Diabetes Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Pacific Diabetes Technologies, Inc.
Free to see. No signup.
More on the people and the money behind Pacific Diabetes Technologies, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Pacific Diabetes Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Pacific Diabetes Technologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch Pacific Diabetes Technologies, Inc. →Get the full cited report on Pacific Diabetes Technologies, Inc.
What the filing shows about Pacific Diabetes Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pacific Diabetes Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Pacific Diabetes Technologies, Inc.'s address as 12172 Sw Garden Pl, Portland, OR 97223.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Pacific Diabetes Technologies, Inc. →
Amended on 2025-11-17: the offering size changed from $3,000,000 to $3,500,000; the amount sold changed from $2,920,000 to $3,385,000; the number of investors changed from 4 to 15. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Pacific Diabetes Technologies, Inc. See pricing
Pacific Diabetes Technologies, Inc. is a registered filer with the SEC (CIK 1835476) and has filed since 2023-09-13. 5 filings are on record, the latest on 2025-11-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Pacific Diabetes Technologies, Inc.'s Form D of 2025-10-20 names Thomas Seidl, Hank Wuh and Christopher Marsh as its officers, directors or promoters.
Its new offerings report $5.48M sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Thomas Seidl is named as Executive Officer and Director and Promoter on the Form D that Pacific Diabetes Technologies, Inc. filed with the SEC on 20 October 2025, one of 3 people that filing names.
Hank Wuh is named as Director on the Form D that Pacific Diabetes Technologies, Inc. filed with the SEC on 20 October 2025, one of 3 people that filing names.
Christopher Marsh is named as Director on the Form D that Pacific Diabetes Technologies, Inc. filed with the SEC on 20 October 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-10-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Pacific Diabetes Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pacific Diabetes Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacific Diabetes Technologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Pacific Diabetes Technologies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Pacific Diabetes Technologies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Pacific Diabetes Technologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Portland
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/pacific-diabetes-technologies-inc-form-d-25000001